News | Heart Valve Technology | October 18, 2022

U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath

Smaller Sheath Simplifies Access and Improves Ease-of-Use

Abiomed’s 14 Fr Impella Low Profile Sheath and dilator set.

Abiomed’s 14 Fr Impella Low Profile Sheath and dilator set. 

 


October 18, 2022 —  The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for its Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement of Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr. As a result of its smaller size and other technological advancements, the Low Profile Sheath will facilitate easier Impella insertion and removal, reduce procedural steps and help improve outcomes. 

The Low Profile Sheath is the first sheath specifically engineered to be compatible with the Impella single-access technique, which removes the need for an additional access site. Additionally, it is designed to: 

Simplify access and ease-of-use by eliminating the peel-away sheath and the need for the re-access sheath for patients who are sent to the intensive care unit. 

Further minimize vascular complications and bleeding. 

Facilitate easier delivery into the vasculature with a hydrophilic coated long-taper dilator, reducing the need for multiple steps of serial dilation. 

Facilitate easier management of the patient during heart pump removal and vascular closure because Impella can be removed directly from the sheath without re-wiring. 

“Abiomed’s Low Profile Sheath is a game changing technological achievement that will further improve patient outcomes by making it even easier for physicians to insert, manage and remove Impella heart pumps,” said Chuck Simonton, MD, Abiomed’s chief medical officer. 

Abiomed will begin a phased roll-out of the Impella Low Profile Sheath this quarter. 

For more information: www.abiomed.com


Related Content

News | Heart Failure

March 5, 2023 — Doctors who received customized electronic health record (EHR) alerts for specific patients were 2.5 ...

Home March 05, 2023
Home
News | Heart Failure

March 4, 2023 - Lexicon Pharmaceuticals, Inc. announced new analyses of results from the SOLOIST-WHF Phase 3 outcomes ...

Home March 04, 2023
Home
News | Heart Failure

March 3, 2023 — Researchers may be able to predict cardiovascular disease – such as atrial fibrillation and heart ...

Home March 03, 2023
Home
News | Heart Failure

February 24, 2023 — Abiomed, Inc., part of Johnson & Johnson MedTech[1], announced that results from a study on Impella ...

Home February 24, 2023
Home
News | Heart Failure

February 23, 2023 — Lexicon Pharmaceuticals, Inc. announced the upcoming presentation of new analyses of results from ...

Home February 23, 2023
Home
News | Heart Failure

February 22, 2023 — CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing and ...

Home February 22, 2023
Home
News | Heart Failure

February 2, 2023 — Technology is continuously evolving, and so is the approach taken by transplant cardiologists at ...

Home February 02, 2023
Home
News | Heart Failure

January 25, 2023 — Adults living in rural areas of the United States have a 19% higher risk of developing heart failure ...

Home January 25, 2023
Home
News | Heart Failure

January 24, 2023 — Leakage of the mitral valve due to degenerative prolapse is a common condition known as primary ...

Home January 24, 2023
Home
News | Heart Failure

January 18, 2023 — Phone calls from a nurse may improve survival for patients treated for heart failure, according to a ...

Home January 18, 2023
Home
Subscribe Now